Company: ABUS
Filing Date: 2025-06-25
Form Type: 8-K
Source: 0001171843-25-004094
Chunk: 0

Company: Arbutus Biopharma Corp
Filing Date: 2025-06-25
Form: 8-K
Item: Item 1.02
Chunk 0
---
Item 1.02. Termination of a Material Definitive Agreement.

In December 2021, Arbutus Biopharma Corporation (“ Arbutus”) entered into a technology transfer and license agreement (the “ License Agreement”) with Qilu Pharmaceutical Co., Ltd. (“ Qilu”), pursuant to which Arbutus granted Qilu an exclusive (except as to certain retained rights), sublicensable, royalty-bearing license, under certain intellectual property owned by Arbutus, to develop, manufacture and commercialize its lead compound, imdusiran, in China, Hong Kong, Macau and Taiwan (“ Greater China and Taiwan”).

In light of Qilu’s pipeline reprioritization efforts and Arbutus’ renewed focus on advancing its pipeline efficiently, on June 20, 2025, Arbutus and Qilu mutually agreed to conclude the strategic partnership and entered into a Termination Agreement filed herewith as Exhibit 10.1. There were no payments associated with the termination and all rights granted under the License Agreement for imdusiran in Greater China and Taiwan have reverted to Arbutus.

The foregoing summary of the material terms of the License Agreement is qualified in its entirety by the complete terms and conditions of the License Agreement, filed with the Securities and Exchange Commission on March 3, 2022 as Exhibit 10.41 to Arbutus’ Annual Report on Form 10-K for the year ended December 31, 2021.

Item 8.01. Other Events.

On June 25, 2025, Arbutus issued a press release announcing the reacquisition of imdusiran rights in Greater China and Taiwan, the termination of the License Agreement with Qilu, and its new Scientific Advisory Board. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference herein.